mAbxience S.L.

Demonstrating a continued momentum for deal-making this year, Spanish biosimilars developer mAbxience has struck another agreement, this time a strategic licensing deal with Corapharm covering an undi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen Pharma giving it Italian rights to an undisclosed biosimilar candidate. The firms said that mAbxience – which is majority

Four biosimilars sponsors – Biocon Biologics, Gedeon Richter, Mabxience and Zentiva – have each received dual positive opinions from the European Medicines Agency’s Committee for Medicinal Products fo